PubMed Health⌕ Search

Biomedical subjects

R Vacarezza

Publications and source records attributed to R Vacarezza.

8 recordsLinked to original sources
PubMed1991

[Treatment of Hodgkin's disease. National Protocol of Antineoplastic Drugs: preliminary report].

We report preliminary results of treatment of Hodgkin disease according to the National Protocol on Antineoplastic Drugs. 37 males and 22 females with a median age of 34 years (range 16 to 76) were treated. Patients with stages I or II received radiotherapy alone or chemotherapy (C-MOPP) followed by radiotherapy. Patients with stages III or IV received radiotherapy and chemotherapy or alternating courses of C-MOPP and ABVD. Complete remission was observed in 74% of 39 patients completing full therapy. Complete remission was more common in patients with nodular sclerosis without B symptoms and under 45 years of age. Actuarial survival at 22 months was 79%, significantly higher for patients with nodular sclerosis compared to patients with lymphocytic depletion. Different treatments in patients at stages I and II or III and IV gave comparable results. Complications included infection with the Chickenpox-Zoster virus, pneumonia and fever of unknown origin. Mortality was associated to older age, complications of treatment or failure to comply with therapy.

Actuarial Analysis↗
PubMed1991

[Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].

The first results of the management of adult non-Hodgkin lymphoma according to the National Protocol are reported. 164 pts (71 female and 93 male), aged 50 (range 15 to 79 years) were included. 89 pts had lymphomas with intermediate, 34 with low and 24 with high grade malignancy. 65% had advanced stages (III and IV). In the low grade malignancy group 38% were in complete remission and actuarial survival at 20 months was 80%. In the intermediate grade group, stages I and II the corresponding values were 79 and 85%; in the intermediate grade stages III and IV, 58 and 69%, and in the high grade group 61 and 77%. Bone marrow toxicity and infections were the main complications. 32 pts have died, 10 of them with drug toxicity complications.

Adolescent↗
PubMed1990

[Cerebral vasodilators].

Cerebral vasodilators (CVD) account for 1.6% of the annual expenditure on drugs in Chile. Two kinds are typified: what we have called orthodox CVD and calcium-channel blockers. They have two main uses in neurology: firstly, in acute ischaemic stroke where orthodox CVD (buflomedil, codergocrine mesylate, and nicergoline) are of no use and may even be harmful whereas calcium-channel blockers seem beneficial in neutralizing free radicals. Secondly they are used in ageing and dementia. These terms are defined and it is seen that they often end up converging. The methodology most often used in evaluating the cognitive benefits of CVD is analyzed; it is clearly plagued with subjectivity. Available literature on CVD is reviewed and no serious evidence to justify their use is found, especially in view of their cost and modest benefit accrued. A sample of the advertisements which appear in various scientific journals is scanned for VDC. It is seen that large transnationals spend 1 page in 10 of all advertising on orthodox CVD in neurological and psychiatric journals in Latin America: in similar journals of European and North American origin not one page was found.

Aging↗
PubMed1990

[Treatment of acute non-lymphoblastic leukemia in adults. Preliminary report from the national protocol on antineoplastic drugs].

After a follow up of 22 months we report results of treatment on 44 patients (22 males), aged 16 to 63 years, with acute non lymphoblastic leukemia. Complete remission was obtained in 22 patients. This was significantly more frequent in patients under 40 years of age with white cell counts under 35,000 and without metabolic complications nor disseminated intravascular coagulation before treatment. Delaying chemotherapy for 5 days after diagnosis was also associated to a better prognosis. Overall actuarial survival rate was 37% at 15 months, 55% for those experiencing a first remission. A total of 25 patients [corrected] have died, 15 during induction of therapy, 7 after complete remission and 3 after failure of induction. Infections are the main cause of death during induction, with a high lethality for sepsis (33%) and pneumonia (40%).

Actuarial Analysis↗
PubMed1989

[Treatment of Hodgkin's lymphoma].

From November 1976 until September 1987, 59 patients with Hodgkin's disease have been admitted and treated with radiotherapy alone or radiotherapy plus elective chemotherapy after been staged according to Stanford's guidelines and following the Ann Arbor's classification. 33 patients were staged I or II, and 26 as stage III or IV. Patients in earlier stages received preferentially radiotherapy alone and those in more advanced stages received radio and chemotherapy. After a median follow-up of 39 months, 100% of patients in stage I, 81.5% of patients in stages II and III A and 45% of patients in stages III B and IV were alive and well. The relapse free survival for patients in stages II and III A was 48.4%, rising to 81.5% after rescue. The use of elective chemotherapy made no difference in survival for stages II B and III A.

Adolescent↗